Promoting Tumorigenesis in Nasopharyngeal Carcinoma, Nedd8 Serves as a Potential Theranostic Target

  • 类型：
  • 作者：Xie, P., Yang, J. P., Cao, Y., Peng, L. X., Zheng, L. S., Sun, R., Meng, D. F., Wang, M. Y., Mei, Y., Qiang, Y. Y., Cao, L., Xiang, Y. Q., Luo, D. H., Yun, J. P., Huang, B. J., Jia, L. J. & Qian, C. N.
  • 期刊：Cell death & disease 8, e2834 (2017)
  • 阅读原文

Nasopharyngeal carcinoma (NPC), is one of the most common human malignancies in south China, it has the highest recurrence rate and treatment resistance. The underlying molecular mechanisms of NPC relapse and treatment tolerance are not fully understood. In this study, the effects of NEDD8 and NEDD8-activating enzyme inhibitor (MLN4924) on NPC were studied both in vitro and in vivo. Immunohistochemical staining of 197 NPC tissues revealed an elevated NEDD8 expression as an unfavorable independent factor in overall survival and disease-free survival rates. NEDD8 expression was positively correlated with a high risk of death and positivity of lymph node metastasis. Depleted NEDD8 expression by shRNA and inhibited by specific inhibitor MLN4924 dramatically suppressed cell proliferation, cell apoptosis, cell cycle arrest, while ectopic NEDD8 exhibited opposing effects. NEDD8 affected cancer stem cell phenotypes of NPC as assessed in vitro using the cell number of side population (SP) by flow cytometry analysis, colony formation assay, sphere formation assay, and tumor initiation ability in vivo. Downregulation of NEDD8 enhanced the susceptibility of NPC cells to cisplatin and radiation. Moreover, we found that MLN4924 suppressed c-Jun degradation in human NPC cells. Taken together, this report revealed that NEDD8 may act as a novel prognostic marker and MLN4924 may serve as a promising therapeutic target for patients with NPC.

文章引用产品